Anthony Schwartz, CEO, Morphiex Therapeutics, shares his thoughts on the leading challenges when targeting the CD47/SIRPa axis.

Click here to download your copy

 

 

Recent News

Hopin FAQs

Read more +

Industry Insights: Taylor Schreiber, Shattuck Labs

Read more +

Industry Insights: Kipp Weiskopf, Whitehead Institute

Read more +